Display options
Cite
Tholomier C, Bienz M, Hueber PA, et al. Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. Can Urol Assoc J. 2014;8(5):195-201doi: 10.5489/cuaj.2016.
Tholomier, C., Bienz, M., Hueber, P. A., Trinh, Q. D., Hakim, A. E., Alhathal, N., Lebeau, T., Benayoun, S., Valdivieso, R., Liberman, D., Saad, F., Lattouf, J. B., Widmer, H., Begin, L., Latour, M., & Zorn, K. C. (2014). Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 8(5), 195-201. https://doi.org/10.5489/cuaj.2016
Tholomier, Côme, et al. "Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 8,5 (2014): 195-201. doi: https://doi.org/10.5489/cuaj.2016
Tholomier C, Bienz M, Hueber PA, Trinh QD, Hakim AE, Alhathal N, Lebeau T, Benayoun S, Valdivieso R, Liberman D, Saad F, Lattouf JB, Widmer H, Begin L, Latour M, Zorn KC. Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. Can Urol Assoc J. 2014 May;8(5):195-201. doi: 10.5489/cuaj.2016. PMID: 25024790; PMCID: PMC4081250.
Copy Download .nbib Format: NLM
Share it on

Can Urol Assoc J. 2014 May;8(5):195-201. doi: 10.5489/cuaj.2016.

Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Côme Tholomier, Marc Bienz, Pierre-Alain Hueber, Quoc Dien Trinh, Assaad El Hakim, Naif Alhathal, Thierry Lebeau, Serge Benayoun, Roger Valdivieso, Dan Liberman, Fred Saad, Jean-Baptiste Lattouf, Hugues Widmer, Louis Begin, Mathieu Latour, Kevin C Zorn

Affiliations

  1. Section of Urology, Department of Surgery, Centre Hospitalier de l'Université de Montréal, Montréal, QC;
  2. Division of Robotic Urology, Department of Surgery, Hopital du Sacre Coeur de Montreal, Montreal, QC;
  3. Section of Urology, Department of Surgery, Centre Hospitalier de l'Université de Montréal, Montréal, QC; ; Division of Robotic Urology, Department of Surgery, Hopital du Sacre Coeur de Montreal, Montreal, QC;
  4. Department of Pathology, Centre Hospitalier de l'Universite de Montreal, Montreal, QC.

PMID: 25024790 PMCID: PMC4081250 DOI: 10.5489/cuaj.2016

Abstract

INTRODUCTION: While RARP (robotic-assisted radical prostatectomy) has become the predominant surgical approach to treat localized prostate cancer, there is little Canadian data on its oncological and functional outcomes. We describe the largest RARP experience in Canada.

METHODS: Data from 722 patients who underwent RARP performed by 7 surgeons (AEH performed 288, TH 69, JBL 23, SB 17, HW 15, QT 7, and KCZ 303 patients) were collected prospectively from October 2006 to December 2013. Preoperative characteristics, as well as postoperative surgical and pathological outcomes, were collected. Functional and oncological outcomes were also assessed up to 72 months postoperative.

RESULTS: The median follow-up (Q1-Q3) was 18 months (9-36). The D'Amico risk stratification distribution was 31% low, 58% intermediate and 11% high-risk. The median operative time was 178 minutes (142-205), blood loss was 200 mL (150-300) and the postoperative hospital stay was 1 day (1-23). The transfusion rate was only 1.0%. There were 0.7% major (Clavien III-IV) and 10.1% minor (Clavien I-II) postoperative complications, with no mortality. Pathologically, 445 men (70%) were stage pT2, of which 81 (18%) had a positive surgical margin (PSM). In addition, 189 patients (30%) were stage pT3 and 87 (46%) with PSM. Urinary continence (0-pads/day) returned at 3, 6, and 12 months for 68%, 80%, and 90% of patients, respectively. Overall, the potency rates (successful penetration) for all men at 6, 12, and 24 months were 37%, 52%, and 59%, respectively. Biochemical recurrence was observed in 28 patients (4.9%), and 14 patients (2.4%) were referred for early salvage radiotherapy. In total, 49 patients (8.4%) underwent radio-therapy and/or hormonal therapy.

CONCLUSIONS: This study shows similar results compared to other high-volume RARP programs. Being the largest RARP experience in Canada, we report that RARP is safe with acceptable oncologic outcomes in a Canadian setting.

References

  1. Eur Urol. 2004 Aug;46(2):188-94 - PubMed
  2. J Urol. 2001 Jun;165(6 Pt 1):1964-6 - PubMed
  3. J Urol. 2007 Feb;177(2):615-9 - PubMed
  4. Cancer. 2002 Oct 15;95(8):1773-85 - PubMed
  5. J Sex Med. 2009 Mar;6(3):809-19 - PubMed
  6. Curr Opin Urol. 2004 Mar;14(2):75-82 - PubMed
  7. Eur Urol. 2003 Aug;44(2):175-81 - PubMed
  8. BJU Int. 2006 Mar;97(3):467-72 - PubMed
  9. Urology. 2008 Jul;72(1):15-23 - PubMed
  10. J Urol. 2005 May;173(5):1701-5 - PubMed
  11. J Clin Oncol. 2005 Apr 20;23(12):2772-80 - PubMed
  12. Urology. 2005 Nov;66(5):1029-33 - PubMed
  13. J Urol. 2003 Jun;169(6):2066-71 - PubMed
  14. Urology. 2002 Nov;60(5):864-8 - PubMed
  15. Crit Rev Oncol Hematol. 2002 Aug;43(2):123-33 - PubMed
  16. Can Urol Assoc J. 2011 Jun;5(3):188-94 - PubMed
  17. Eur Urol. 2001 Jul;40(1):38-45 - PubMed
  18. Can Urol Assoc J. 2010 Feb;4(1):13-25 - PubMed
  19. BJU Int. 2012 Sep;110(6):821-7 - PubMed
  20. Can J Urol. 2013 Oct;20(5):6957-61 - PubMed
  21. Cancer. 2007 Nov 1;110(9):1951-8 - PubMed
  22. Curr Urol Rep. 2005 Feb;6(1):45-8 - PubMed
  23. J Wound Ostomy Continence Nurs. 2007 May-Jun;34(3):270-9; quiz 280-1 - PubMed
  24. CMAJ. 2000 Apr 4;162(7):987-92 - PubMed
  25. BJU Int. 2009 Oct;104(7):991-5 - PubMed
  26. Can Urol Assoc J. 2011 Jun;5(3):161-6 - PubMed
  27. Eur Urol. 2013 Jul;64(1):19-25 - PubMed
  28. Eur Urol. 2012 Apr;61(4):679-85 - PubMed
  29. J Urol. 2010 Jan;183(1):145-50 - PubMed
  30. Can Urol Assoc J. 2013 Mar-Apr;7(3-4):116-21 - PubMed
  31. Urology. 2004 May;63(5):819-22 - PubMed
  32. J Endourol. 2008 Jun;22(6):1303-9 - PubMed
  33. Urology. 2009 Sep;74(3):611-6 - PubMed
  34. Eur Urol. 2012 Sep;62(3):405-17 - PubMed
  35. BJU Int. 2006 Jul;98(1):47-9 - PubMed
  36. BJU Int. 2009 Nov;104(10):1428-35 - PubMed
  37. Can Urol Assoc J. 2013 Sep-Oct;7(9-10):326-32 - PubMed
  38. J Urol. 2003 Jun;169(6):2045-8 - PubMed
  39. Can Urol Assoc J. 2010 Aug;4(4):237-41 - PubMed
  40. J Urol. 2005 Jul;174(1):269-72 - PubMed
  41. Can J Urol. 2013 Dec;20(6):7073-8 - PubMed

Publication Types